文献速递消化系统肿瘤

肝细胞癌:选择胜者——酪氨酸激酶抑制剂对比免疫肿瘤药物联合方案

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
PubMed 文献 · J Clin Oncol · 2022-06-01

过去4年晚期肝细胞癌治疗格局发生巨大变化,免疫治疗引入后出现持续双位数客观缓解率且总生存改善良好的方案。阿替利珠单抗联合贝伐珠单抗在IMbrave150研究中较索拉非尼改善结局;COSMIC-312中卡博替尼联合阿替利珠单抗较索拉非尼改善无进展生存但总生存无改善且缓解率低于预期;HIMALAYA研究达到主要终点。

要点

  • 阿替利珠单抗联合贝伐珠单抗在IMbrave150中较索拉非尼改善结局。
  • COSMIC-312中卡博替尼联合阿替利珠单抗较索拉非尼改善无进展生存,但总生存无改善且缓解率低于预期。
  • HIMALAYA研究中度伐利尤单抗联合曲美木单抗及单药度伐利尤单抗均达到改善总生存的主要终点。

核心结论

  • 晚期肝细胞癌治疗选择增多,免疫治疗引入后出现持续双位数客观缓解率且总生存改善良好、副作用谱有利的方案。

研究设计与样本

  • 本文基于当前对 evolving 方案安全性和疗效的认识,讨论现代晚期肝细胞癌治疗决策相关问题,旨在为临床医生提供优化患者结局的知识。

主要发现

  • IMbrave150研究中阿替利珠单抗联合贝伐珠单抗较索拉非尼改善结局。
  • COSMIC-312研究中卡博替尼联合阿替利珠单抗较索拉非尼改善无进展生存,但总生存无改善,缓解率低于预期。
  • HIMALAYA研究中度伐利尤单抗联合曲美木单抗达到改善总生存的主要终点,单药度伐利尤单抗也显示非劣效。
  • HIMALAYA中该联合方案未改善无进展生存,客观缓解率与单药度伐利尤单抗相比似乎无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment landscape for advanced hepatocellular carcinoma has changed dramatically over the past 4 years. We now have numerous options for patients in frontline, second-line, and beyond. The most significant impact has been the introduction of immunotherapy into our treatment paradigms. We now have regimens that induce consistent double-digit objective response rates and markedly improve overall survival (OS) with favorable side effect profiles. The combination of atezolizumab and bevacizumab has demonstrated that the combination of targeting programmed death-ligand 1 and the vascular endothelial growth factor axis can improve outcomes versus sorafenib in the IMBrave150 study. Results from the COSMIC-312 study evaluating the multikinase vascular endothelial growth factor receptor, hepatocyte growth factor receptor, and AXL tyrosine kinase receptor inhibitor cabozantinib in combination with atezolizumab improved progression-free survival versus sorafenib, but at this time, there is no improvement in OS and response rates were lower than expected. Additional data with similar combinations are awaited on the basis of encouraging early-phase data. In addition, the combination of cytotoxic T-lymphocyte-associated protein 4 and programmed cell death-1/programmed death-ligand 1 targeting is yielding similar promising early results, and the phase III HIMALAYA study met its primary end points of improving OS versus sorafenib for durvalumab plus tremelimumab and demonstrated noninferiority for single-agent durvalumab as well. However, this combination did not improve progression-free survival and objective response rates with this combination did not seem significantly different from that with single-agent durvalumab. Although there are still knowledge gaps in this rapidly changing landscape, we will address some of the important questions relevant to making therapeutic decisions in the management of advanced hepatocellular carcinoma in the modern era on the basis of our current knowledge of the safety and efficacy of these evolving regimens. The goal is to provide clinicians with the knowledge needed to optimize outcomes for their patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bejjani AC, Finn RS. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol. 2022. PMID: 35649192. doi:10.1200/JCO.21.02605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。